Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND

News SummaryMost relevantAll newsSector news 

Ligand Pharmaceuticals Inc. : SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals Incorporated

05/17/2013 | 12:55pm US/Eastern

NEW YORK, May 17, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

To get more information, click here: http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/. There is no cost or obligation to you.

If you own common stock in Ligand Pharmaceuticals Incorporated and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

React to this article
09/29 LIGAND PHARMACEUTICALS : Expands Captisol License and Supply Agreements with SAG..
09/17 LIGAND PHARMACEUTICALS : Entry into a Material Definitive Agreement (form 8-K)
09/16 LIGAND PHARMACEUTICALS : Other Events (form 8-K)
09/10 LIGAND PHARMACEUTICALS : Amendments to Articles of Inc. or Bylaws; Change in Fis..
09/02 LIGAND PHARMACEUTICALS : Revolade® Receives EU Approval as First-in-Class Therap..
08/24 LIGAND PHARMACEUTICALS : FDA Expands Use of Promacta® to Include Treatment of Ch..
08/15 LIGAND PHARMACEUTICALS : SEC Receives Insider Trading Form Involving Ligand Phar..
08/08 LIGAND PHARMACEUTICALS : SEC Receives Insider Trading Form Involving Ligand Phar..
08/07 AMGEN : Ligand Releases 2Q 2015 Financial Results
08/06 LIGAND PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)